Home
Help
Coronavirus (COVID-19) Alerts and Registration
Alert Compliance Data
Other Safety Information
Login
Javascript is disabled because of the browser settings on this machine. So, a few features might not be available.
Coronavirus (COVID-19) Alerts and Registration
This page displays a consolidated list of alerts we have issued on Coronavirus. The dates in the list below are the issue dates of the alerts and will take you to the alert once clicked.
29 March 2023 (NICE MTA - Treatment recommendations)
29 November 2022 (Interleukin-6 inhibitors (tocilizumab or sarilumab) for adult patients hospitalised due to COVID-19)
28 November 2022 (Baricitinib for patients hospitalised due to COVID-19 (Adults and Children aged 2 years and over)
28 November 2022 (Remdesivir for patients hospitalised due to COVID-19)
28 November 2022 (treatment of hospital-onset COVID-19 in Adults and Children
28 November 2022 (treatment for highest risk non-hospitalised patients (Adults and Children) with COVID-19
04 July (Palivizumab)
30 May 2022
Antivirals or Neutralising Antibodies for Non-Hospitalised Patients with COVID-19
30 May 2022 Antivirals or Neutralising Monoclonal Antibodies in the treatment of Hospital-Onset COVID-19
5 May 2022 Baricitinib for Patients Hospitalised Due to COVID-19 (Adults and Children Aged 2 Years and Over)
24 February 2022 (Remdesivir)
24 February 2022 (Antivirals and neutralising monoclonal antibodies in hospitalised patients)
31 Janurary 2022 Interleukin-6 inhibitors (tocilizumab or sarilumab) for adult patients hospitalised due to COVID-19
28 January 2022 (Palivizumab passive immunisation against respiratory syncytial virus (RSV) in at risk pre-term infants)
27 January 2022 (
Antivirals and neutralising monoclonal antibodies in the treatment of COVID-19 in hospitalised patients)
27 January 2022 (
Antivirals or neutralising monoclonal antibodies (nMABs) for non-hospitalised patients with COVID-19)
24 December 2021 (
Neutralising monoclonal antibody and intravenous antiviral treatments for patients in hospital with COVID-19 infection)
16 December 2021 (Neutralising monoclonal antibodies or antivirals in hospitalised patients)
16 December 2021 (Neutralising monoclonal antibodies or antivirals for non-hospitalised patients)
14 December 2021 (Withdrawal of the Recommendation for Consideration of Inhaled Budesonide as a Treatment Option for COVID-19)
08 December 2021 (Neutralising monoclonal antibodies)
28 November 2021 (Variant B.1.1.529)
04 November 2021 (Ronapreve)
17 September 2021 (Ronapreve)
12 September 2021 (
Interleukin-6 inhibitors)
02 September 2021 (CPAP)
29 June 2021 (Palivizumab)
14 June 2021 (Update: Remdesivir)
09 June 2021 - PPE and heat stress
13 April 2021 - (Propofol - supply update)
12 April 2021 (Budesonide)
17 March 2021 (Convalescent Plasma)
12 March 2021 (Updated information on PCR testing)
24 February 2021 (Fang Tian FFP3 RECALL)
18 February 2021 (Fang Tian FFP3 masks)
17 February 2021 (IL6 inhibitors
tocilizumab or sarilumab
update)
03 February 2021(Propofol supply disruption)
01 February 2021 (IL6 inhibitors)
28 January 2021 (Antimicrobials)
14 January 2021 (Methylprednisolone supply disruption
12 January 2021 (Supporting doctors)
08 January 2021 (IL6 Inhibitors)
31 December (Vaccine programme)
24 December (SARS-CoV-2 virus new variants)
23 December (indemnity arrangements)
15 December (Azithromycin)
04 December (Vaccines and research)
25 November (Tocilizumab)
19 November (Oxygen supply and fire safety)
11 November (Supporting doctors throughout the second COVID-19 wave)
07 November (mink-variant SARS-CoV-2 virus in Denmark
06 November (Remdesivir)
07 October (Roche reagent)
29 September (Remdesivir Supply Disruption)
10 September (withdrawal of 17 April PPE guidance)
03 September 2020 (Updated: Remdesivir)
03 September 2020 (
Corticosteroids in the treatment of suspected or confirmed COVID-19)
18 August 2020 (Treatment trials)
20 July 2020 (Cardinal type IIR Face masks)
03 July 2020 (Remdesivir interim clinical commissioning policy)
23 June 2020 (PPE and heat stress)
16 June 2020 (Dexamethasone use in COVID-19)
09 June 2020 (Second update - Early access to remdesivir)
08 June 2020 (Blood sample collection kits)
03 June 2020 (Update - Early access to remdesivir)
26 May 2020 (Early access to remdesivir)
18 May 2020 (Change to case definition)
14 May 2020 (Care home testing)
10 May 2020 (Tiger eye protector)
06 May 2020 (update on clinical trials)
05 May 2020 (launch of Yellowcard pandemic portal)
28 April 2020 (Ativan (lorazepam) injection, supply disruption)
22 April 2020 (haemofiltration kits and fluids, supply disruption)
17 April 2020 (PPE)
16 April 2020 (neuromuscular blocking agents, supply disruption)
14 April 2020 (Ibuprofen and coronavirus)
10 April 2020 (haemofiltration systems)
10 April 2020 (sent to GPs only, shielding)
06 April 2020 (oxygen usage)
03 April 2020 (sent to GPs only, shielding)
03 April 2020 (PPE guidance update)
02 April 2020 (clinical negligence indemnity)
02 April 2020 (tension pneumothorax)
01 April 2020 (Clinical trials)
01 April 2020 (interruption of high flow nasal oxygen during transfer)
01 April 2020 (high flow oxygen therapy devices)
21 March 2020 (sent to GPs only, shielding)
17 March 2020 (Anti-inflammatory medicines)
13 March 2020 (Community swabbing services)
12 March 2020
10 March 2020
05 March 2020
25 February 2020
07 February 2020
03 February 2020 (Advice to primary and community care)
31 January 2020
23 January 2020
Contact our helpdesk
Email:
safetyalerts@mhra.gov.uk